

Investigational Pipeline

The agents below are not approved for the uses listed by any regulatory agency as efficacy and safety have not been established.

Efgartigimod alfa (IV)

Efgartigimod alfa and hyaluronidase-qvfc (SC)

Target:
FcRn

Ongoing
Clinical Trials

Preclinical

Phase 1

Proof of Concept

Registrational



Primary Immune Thrombocytopenia (IV)



Seronegative Generalized Myasthenia Gravis (IV)



Pediatric Generalized Myasthenia Gravis (IV/SC)



Ocular Myasthenia Gravis (SC)



Thyroid Eye Disease (SC)



Myositis (IMNM, ASyS, DM)(SC)



Sjogren's Disease (SC)

Lupus Nephropathy (IV)



Systemic Sclerosis (SC)



Antibody Mediated Rejection (SC)

Empasiprubart

Target:
C2



Multifocal Motor Neuropathy



Delayed Graft Function



Chronic Inflammatory Demyelinating Polyradiculoneuropathy

ARGX-119

Target:
MuSK



Congenital Myasthenic Syndrome



Amyotrophic Lateral Sclerosis

Spinal Muscular Atrophy

Neurology Hematology/Rheumatology Nephrology Endocrinology

Abbreviations: ASyS, antisynthetase syndrome; C2, complement factor 2; DM, dermatomyositis; FcRn, neonatal Fc receptor; IMNM, immune-mediated necrotizing myopathy; IV, intravenous; MuSK, muscle-specific tyrosine kinase; SC, subcutaneous

argenx

©2025 argenx MED-US-a117-2400012 v5.0
September 2025